Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,438
Out of 5,118 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $23.33 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $69.62 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $780.50 | +8.90% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.26 | +1,328.57% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.04 | +5,669.23% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.55 | +480.65% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $7.76 | +338.14% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $176.83 | +84.92% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $35.84 | +1,484.82% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $459.78 | -38.88% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.62 | +393.83% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.00 | +9,724.56% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $329.63 | -10.51% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $124.91 | -31.15% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $30.53 | +57.22% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.78 | +342.48% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.16 | +165.10% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.71 | +192.40% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $99.29 | +0.72% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $211.02 | -4.75% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $77.64 | +9.48% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.89 | +101.38% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $21.82 | +894.50% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $50.91 | -5.72% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $18.96 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $398.82 | -61.39% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $60.04 | +93.20% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.10 | +1,637.70% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $9.14 | +206.35% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $186.91 | -56.13% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $502.90 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.25 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.33
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.62
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $780.50
Upside: +8.90%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.26
Upside: +1,328.57%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.04
Upside: +5,669.23%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.55
Upside: +480.65%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $7.76
Upside: +338.14%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $176.83
Upside: +84.92%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $35.84
Upside: +1,484.82%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $459.78
Upside: -38.88%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.62
Upside: +393.83%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.00
Upside: +9,724.56%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $329.63
Upside: -10.51%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $124.91
Upside: -31.15%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $30.53
Upside: +57.22%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $6.78
Upside: +342.48%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.16
Upside: +165.10%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.71
Upside: +192.40%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $99.29
Upside: +0.72%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $211.02
Upside: -4.75%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $77.64
Upside: +9.48%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.89
Upside: +101.38%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $21.82
Upside: +894.50%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $50.91
Upside: -5.72%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $18.96
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $398.82
Upside: -61.39%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $60.04
Upside: +93.20%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.10
Upside: +1,637.70%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $9.14
Upside: +206.35%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $186.91
Upside: -56.13%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $502.90
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.25
Upside: -